Provectus Pharmaceuticals, Inc. : BioCentury covers news of Provectus' Type C meeting with FDA

REPRINT FROM JANUARY 6, 2014

THE BERNSTEIN REPORT ON BI OBUSINESS ™

Article Reprint • Page 1 of 1

Provectus Biopharmaceuticals Inc. (OTCBB:PVCT), Knoxville, Tenn. Business: Cancer

On Dec. 17, 2013, Provectus Pharmaceuticals said shareholders approved proposals to change the company's name to Provectus Biopharmaceuticals Inc. and reincorporate in Delaware from Nevada. The biotech said reincorporating in Delaware gives the company more "flexibility, clarity and predictability" with respect to corporate governance and said corporate laws in the state are more "comprehensive, widely-used and extensively interpreted" than the corporate laws of other states. Provectus has completed a Phase II trial of PV-10 to treat metastatic melanoma. The biotech met with FDA on Dec. 16 to determine a path forward for the sterile injection containing 10% rose bengal disodium and expects minutes from the meeting on Jan. 15.

BioCentury®

T HE BERNSTEIN REPORT ON BIOBUSINESS

DAVID FLORES

President & CEO

KAREN BERNSTEIN, Ph.D.

Chairman & Editor-in-Chief

PO Box 1246

San Carlos CA 94070-1246

Voice: 650-595-5333

Fax: [phone]

www.biocentury.com

BioCentury®, The BioCentury 100, and The Clear Route are trademarks of BIOCENTURY PUBLICATIONS INC. All contents © Copyright 2014, BIOCENTURY PUBLICATIONS INC. ALL RIGHTS RESERVED. No part of this publication may be reproduced, photocopied or reproduced in any form, retransmitted, or stored in a retrieval system without prior written consent of the publisher.

The contents of this publication are gathered from sources believed to be reliable, but in any case are not warranted by the publisher for a particular use or purpose. Also, the content and opinions herein may change without notice and do not constitute investment advice.